Similarly, immunofluorescence staining revealed strong nuclear staining of ubH2AK119 that colocalizes with Hoechst chromatin staining in control-treated tumors, whereas treatment with Unesbulin significantly reduced the number of ubH2AK119 positive foci (Fig. 1E), further confirming BMI-1 activity is being targeted via Unesbulin, resulting in in vivo tumor shrinkage. The gene discussed is BMI1; the disease is neoplasm.